• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Avadel's Once-Nightly Narcolepsy Drug Hits Three Co-Primary Endpoints in Late-Stage Trial

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Apr 27, 2020 at 07:32: PM
via Dublin, Ireland-based Avadel Pharma announced positive topline data from its pivotal Phase III REST-ON clinical trial of FT218 for excessive daytime sleepiness and cataplexy in patients with narcolepsy. Company shares rocketed 30% in premarket trading in response to the news.

article source
 

<



Similar threads

cafead
Jazz brings the noise to the FDA with lawsuit over approval of Avadel&#039;s narcolepsy...
Replies
0
Views
622
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Avadel Pharma says its sleep disorder drug remains under FDA review
Replies
0
Views
16
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
With FDA nod for Lumryz, Avadel is set to Jazz up the narcolepsy market
Replies
0
Views
176
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Avadel gets tentative FDA nod for rival to Jazz narcolepsy drug
Replies
0
Views
205
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Jazz’s toehold on sleep market slips with tentative Avadel FDA approval
Replies
0
Views
527
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote